AFRICURE PHARMACEUTICALS LTD

ABRIDGED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED 30 JUNE 2026

Q1 FY 2026–27

Stronger Margins, Sharper Focus.

Incorporated in the Republic of Mauritius | Registration number: C145852 C1/GBL | Registered office: c/o Ocorian (Mauritius) Limited, Ocorian Tower, Nexera, Lot 7, Côte d'Or Technopole, Minissy, Moka, Mauritius
("Africure" or "the Company"; together with its subsidiaries, the "Group")

DIRECTORS' COMMENTARY

The Board of Directors of Africure Pharmaceuticals Ltd presents the unaudited results for the quarter ended 30 June 2026. Africure operates as an African-focused pharmaceutical manufacturing and distribution platform, serving essential healthcare markets across multiple countries.

The first quarter was defined by the quality of earnings rather than the size of them. Revenue from continuing operations grew 6.4%, but the more meaningful movement was underneath: gross margin rose five points, the cost base came down 12%, and EBITDA rose 79% on essentially flat reported revenue. Growth came from French West Africa and Southern Africa, while Tanzania had a soft dispatch quarter on order timing rather than lost demand.

The balance sheet was deliberately positioned for the second half. Inventory was rebuilt ahead of anticipated volumes, funded largely through supplier credit, and cash tightened as a result. Converting that stock into dispatch is management's first priority for the coming quarter.

"Margin, cost and EBITDA all moved the right way – the task now is converting stock into dispatch."

HIGHLIGHTS OF PERFORMANCE

- Revenue from continuing operations grew 6.4% to USD 5.75 million (Q1 FY 2025–26: USD 5.40 million). Reported revenue was broadly flat at USD 5.75 million.
- Gross margin strengthened to 47% from 42%, led by a richer retail and branded product mix and continued pricing discipline.
- EBITDA rose 79% to USD 0.80 million (from USD 0.44 million), with EBITDA margin improving to 13.8% from 7.8%.
- The operating cost base was 12% lower at USD 1.93 million (from USD 2.18 million), led by a 24% reduction in other operating expenses as prior-year transaction costs rolled off.
- Growth was broad-based outside East Africa: Burkina Faso grew 125%, Botswana 137%, Zambia 94% and Cameroon 29%, with Mali contributing its first quarter of revenue. Tanzania declined 17% on generics and institutional dispatch timing, while Tanzania branded sales grew 30%.
- Market concentration continued to ease – Tanzania now represents 45% of group revenue (from 55%), French West Africa 34% (from 22%), and private-sector revenue held at 76% of the total.
- The net loss for the period narrowed to USD 0.72 million (from USD 0.76 million), with finance costs flat at USD 0.86 million.
- Inventory was built up 12% to USD 8.07 million ahead of second-half volumes, largely in raw and packing materials; trade payables rose to USD 7.96 million and closing cash stood at USD 0.53 million.
- The Board has not declared any dividend for the period.

OUTLOOK FOR THE YEAR

- Restore Tanzania generics and institutional dispatch, where orders are available, and convert the first-quarter inventory build into second-quarter despatches.
- Hold Cameroon's improving manufacturing trajectory, scale the new Mali entry, and sustain the momentum in Burkina Faso and Zambia, with Botswana tender supply treated as further upside.
- Complete the divestment of the Ethiopia operations, with proceeds earmarked to reduce the Group's senior debt facility.
- Maintain working capital discipline – collect against overdue receivables, hold operating costs at the first-quarter run rate, and release cash by bringing working capital days back toward plan.
- Approximately USD 4.75 million of deferred revenue remains positioned to convert into revenue during FY 2026–27.

The Board believes the operating model is working: margin, cost and EBITDA all improved on flat revenue. The immediate opportunity is throughput – converting the stock and order book already in place into despatches – and management's actions for the second quarter are directed squarely at that.

UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

All amounts in USD unless otherwise stated

Particulars	30-Jun-26 Unaudited	31-Mar-26 Audited
ASSETS		
Non-current assets		
Goodwill	2,821,068	2,785,198
Property, plant and equipment	17,690,006	17,879,866
Intangible assets	35,501	34,310
Right of use assets	1,850,926	1,728,101
Total non-current assets	**22,397,501**	**22,427,474**
Current assets		
Inventories	8,069,079	7,178,493
Trade receivables	12,051,807	12,023,435
Cash and cash equivalents	533,109	1,474,285
Other assets	3,048,189	2,536,367
Total current assets	**23,702,184**	**23,212,580**
Total assets	**46,099,685**	**45,640,055**
EQUITY AND LIABILITIES		
Equity share capital and share premium	10,881,853	10,881,853
Equity share capital pending allotment	7,762,672	7,762,672
(Accumulated losses)/Retained earnings	(4,425,626)	(3,799,192)
Other reserves	(3,339,383)	(3,792,338)
Capital and reserves attributable to owners of the Company	**10,879,516**	**11,052,995**
Non-controlling interests	(537,762)	(440,006)
Non-current liabilities		
Borrowings	16,381,485	16,442,808
Operating lease liabilities	3,422,381	3,309,550
Deferred tax liabilities	1,269,977	1,302,992
Total non-current liabilities	**21,073,843**	**21,055,350**
Current liabilities		
Borrowings	5,031,789	5,089,369
Trade and accounts payables	7,958,536	7,379,731
Other liabilities	1,493,634	1,302,574
Operating lease liabilities	151,534	151,534
Current tax liabilities	48,595	48,508
Total current liabilities	**14,684,088**	**13,971,716**
Total equity and liabilities	**46,099,685**	**45,640,055**
Net Asset Value	**1.16**	**1.17**

UNAUDITED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

All amounts in USD unless otherwise stated

Particulars	Quarter ended 30-Jun-26	Quarter ended 30-Jun-25
Continuing operations		
Revenue	5,746,317	5,711,050
Other income	13,812	230,092
	5,760,129	**5,941,142**
Cost of raw materials and finished goods	3,037,241	3,313,099
Employee benefit expenses	1,019,760	995,013
Other expenses	907,663	1,188,123
	4,964,664	**5,496,235**
Profit before finance cost, depreciation and tax (EBITDA)	**795,465**	**444,907**
Finance costs	(862,406)	(863,432)
Depreciation and amortisation	(306,987)	(254,290)
Loss before income tax	**(373,928)**	**(672,815)**
Income tax expense – current tax	(278,264)	(82,753)
Loss for the period from continuing operations	**(652,192)**	**(755,568)**
Loss for the period from discontinued operations	(72,000)	–
Loss for the period	**(724,192)**	**(755,568)**
Attributable to: Owners of the Company	(626,434)	(649,562)
Attributable to: Non-controlling interests	(97,758)	(106,007)
Basic and diluted loss per share (USD)	(0.07)	(0.07)
Weighted average number of shares	9,417,500	9,417,500

CONSOLIDATED STATEMENT OF CASHFLOWS

All amounts in USD unless otherwise stated

Particulars	Quarter ended 30-Jun-26	Quarter ended 30-Jun-25
Net cash used in operating activities	(171,477)	(189,284)
Net cash from investing activities	114,252	26,782
Net cash used in financing activities	(883,951)	(666,661)
Net decrease in cash and cash equivalents	**(941,176)**	**(829,113)**
Cash and cash equivalents at the beginning of the period	1,474,285	1,325,587
Cash and cash equivalents at the end of the period	**533,109**	**496,474**

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

All amounts in USD unless otherwise stated

Particulars	Group					
	Share capital and share premium	Retained earnings	Other Reserves	Equity attributable to owners of the Company	Non-Controlling interests	Total equity
Balance as at 1-Apr-25	**18,644,525**	**1,173,731**	**(4,259,196)**	**15,559,060**	**(306,131)**	**15,252,929**
Loss for the year	–	(649,562)	666,468	16,906	(106,007)	(89,101)
Other reserves				–	(152,470)	(152,470)
Balance as at 30-June-25	**18,644,525**	**524,169**	**(3,592,728)**	**15,575,966**	**(564,608)**	**15,011,358**
Balance as at 1-Apr-26	**18,644,525**	**(3,799,192)**	**(3,792,338)**	**11,052,995**	**(440,004)**	**10,612,991**
Loss for the year	–	(626,434)	452,955	(173,479)	(97,758)	(271,237)
Balance as at 30-June-26	**18,644,525**	**(4,425,626)**	**(3,339,383)**	**10,879,516**	**(537,762)**	**10,341,754**

NOTES TO THE ACCOUNTS

1. The total number of ordinary shares in issue by the Company is 9,417,500 and the number of preference shares in issue is 1,930.
2. The company is required to publish its abridged consolidated unaudited financial results for the three months ended 30 June 2026 in terms of the Listing Rule 12.19 of the SEM.
3. The abridged unaudited consolidated financial statements for the three months ended 30 June 2026 ("abridged unaudited consolidated financial statements") have been prepared in accordance with the measurement and recognition requirements of IFRS, the information contained in IAS 34: Interim Financial Reporting, and the SEM Listing Rules, using the same accounting policies as those of the audited consolidated financial statements for the year ended 31 March 2026.
4. These abridged unaudited consolidated financial statements have not been reviewed or audited by the Company's external auditors. They were approved by the Board on [date].
5. Copies of the abridged unaudited consolidated financial statements are available free of charge, upon request, at the Registered Office of the Company at c/o Ocorian Corporate Services (Mauritius) Limited, Ocorian Tower, Nexera, Lot 7, Côte d'Or Technopole, Minissy, Moka, Mauritius.
6. This communiqué is issued pursuant to SEM Listing Rules 11.3 and 12.19. The Board accepts full responsibility for the accuracy of the information contained in this communiqué.

Contact person: Mr Vashish Bisnathsing.

FOR FURTHER INFORMATION

Perigeum Capital Ltd
SEM Authorised Representative and Sponsor

Ocorian Corporate Services (Mauritius) Limited
Company Secretary